Revenue
$79.67B
Fiscal year ended 2026-06-30Operating income
Unavailable
Fiscal year ended 2026-06-30Free cash flow
Unavailable
Fiscal year ended 2026-06-30ELI LILLY & Co (LLY) reported revenue of $79.67B and net income of $26.71B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from ELI LILLY & Co’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $79.67B |
| Cost of revenue | $13.22B |
| Gross profit | $66.44B |
| Operating income | Unavailable |
| Net income | $26.71B |
| Research & development | Unavailable |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $33.60B |
| Income tax expense | $6.88B |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $12.24B |
| General & administrative | Unavailable |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $8.95B |
| Total assets | $142.28B |
| Current assets | $64.67B |
| Total liabilities | Unavailable |
| Current liabilities | $47.74B |
| Total equity incl. NCI | $33.88B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $16.79B |
| Accounts receivable | $20.08B |
| Goodwill | $8.85B |
| Long-term debt | $47.86B |
| Accounts payable | $6.11B |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $28.08B |
| Capital expenditures | Unavailable |
| Investing cash flow | -$25.10B |
| Financing cash flow | $2.61B |
| Net change in cash | $5.57B |
| Stock-based compensation | $649.00M |
| Common dividends paid | $5.78B |
| Common share repurchases | $6.17B |
| Depreciation & amortization | $2.10B |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | Unavailable |
| Gross margin | 83.4% |
| Operating margin | Unavailable |
| FCF margin | Unavailable |
| SBC / revenue | 0.8% |
| Current ratio | 1.35x |
| Revenue YoY growth | 49.6% |
| Net margin | 33.5% |
| R&D / revenue | Unavailable |
| CapEx / revenue | Unavailable |
| Long-term debt / equity | 1.41x |
| Effective tax rate | 20.5% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LLY in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-04-30View SEC filing
10-K · Filed 2026-02-12View SEC filing
10-Q · Filed 2025-10-30View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-01View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.